Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Caps

How do you think CELG will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,305 Outperform
77 Underperform
 

All-Star Players

451 Outperform
12 Underperform
 

Wall Street

28 Outperform
1 Underperform
 

Top CELG Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFPencils (99.90)
Submitted May 21, 2018

Taking a bit of a flyer on this one given the leadership shuffling going on and questions surrounding some drugs in its pipeline. But despite the near-term challenges, Celgene is still producing more than $3.7 billion in FCF annually and is now… More

NetscribeBiotech (95.03)
Submitted February 22, 2007

Celgene is a biopharmaceutical company focused on novel therapies to treat a broad range of hematopoietic, immunological, neuronal, and cancerous conditions. Celgene currently markets Thalomid for ENL and multiple myeloma, Revlimid for… More

CELG VS S&P 500 (SPY)

Fools bullish on CELG are also bullish on:

Fools bearish on CELG are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CELG.

Recs

0
Member Avatar wolfhounds (66.11) Submitted: 9/29/2018 2:16:37 PM : Outperform Start Price: $90.18 CELG Score: -2.64

The stock is cheap in a world of one drug biotech companies. There have been some failures but it has a deep pipeline.

Recs

0
Member Avatar anathestalker (41.83) Submitted: 9/11/2018 8:50:17 AM : Outperform Start Price: $88.67 CELG Score: -2.63

Unbelievable

Recs

0
Member Avatar XMFRendezvous (78.15) Submitted: 9/6/2018 12:12:30 PM : Outperform Start Price: $93.95 CELG Score: -7.07

Some investors have concerns that Celgene may be a one-trick pony when it comes to blockbuster cancer treatment Revlimid. However Celgene continues to pump out cash, buy back shares at discounted prices, and invest in R&D. While there is potential risk that Revlimid may not prop up the company forever, I think the market is discounting this risk factor too much, and even giving a premium to more uncertain Biotech companies that do not enjoy the cash cow products Celgene does. Because of it's scale and cash flow, Celgene has been described as a biotech hedge fund of sorts, as they acquire smaller players like Abraxis recently.

Forward earnings for this company are a meager 8x, meaning analysts are quite dim on their ability for future growth. Its trailing earnings are 34x, but if the growth story persists, Celgene could be worth quite a lot more than it is today.

Leaderboard

Find the members with the highest scoring picks in CELG.

Score Leader

InvestorDeb

InvestorDeb (70.51) Score: +432.42

The Score Leader is the player with the highest score across all their picks in CELG.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
martyc484 < 20 9/15/2006 Outperform 3Y $20.35 +307.62% +121.00% +186.62 1 Comment
poang 24.71 9/15/2006 Outperform 3Y $20.47 +305.33% +121.52% +183.80 0 Comment
predfern 55.67 9/15/2006 Outperform 5Y $20.47 +305.33% +121.52% +183.80 1 Comment
shanedawg 75.88 9/16/2006 Outperform 1Y $20.50 +304.73% +121.02% +183.71 0 Comment
nepedal < 20 9/21/2006 Outperform 3Y $20.55 +303.65% +121.49% +182.16 1 Comment
MYSTICQUEEN 73.13 9/21/2006 Outperform 3Y $20.62 +302.38% +121.50% +180.88 0 Comment
pharmaway < 20 9/14/2006 5/6/2008 Outperform 1Y $20.55 +303.65% +123.78% +179.87 1 Comment
jolen168 < 20 9/14/2006 Outperform 3Y $20.59 +302.96% +123.29% +179.68 0 Comment
littleboyblue2 64.99 9/14/2006 Outperform 3M $20.59 +302.96% +123.29% +179.68 0 Comment
bronxboston 25.01 9/14/2006 Outperform 1Y $20.59 +302.96% +123.29% +179.68 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
Anonymous331 35.25 6/18/2018 Outperform 5Y $77.21 +7.43% +0.06% +7.38 0 Comment
Anonymous331 35.25 1/14/2016 Outperform 5Y $103.50 +13.28% +12.24% +1.03 11/9/2016 @ $117.24 0 Comment
TrackPiperJaff 85.65 4/25/2014 Outperform NS $70.91 +16.99% +47.64% -30.65 0 Comment
TrackGoldmanSach 75.27 1/6/2014 Underperform NS $82.95 +0.01% +50.65% +50.65 0 Comment
TrackCreditSuiss 89.00 12/10/2013 Outperform NS $85.27 -2.72% +52.72% -55.44 0 Comment
TrackUBS 90.82 12/5/2013 Outperform NS $81.54 +1.73% +54.06% -52.33 0 Comment
TrackArgus 87.03 6/13/2013 Outperform NS $59.49 +39.44% +70.98% -31.54 0 Comment
TrackZacks < 20 10/25/2012 Underperform 3M $37.16 +1.32% -2.09% -3.40 11/12/2012 @ $37.65 1 Comment
TrackWayneRogers 62.76 7/27/2012 Outperform 3M $35.30 +134.99% +99.31% +35.68 0 Comment
TrackArgus 87.03 7/2/2012 Outperform NS $32.34 +53.08% +10.01% +43.08 1/28/2013 @ $49.50 0 Comment
TrackCowenandCo 77.75 6/26/2012 Outperform NS $31.00 +167.56% +109.87% +57.69 0 Comment
TrackPoisedTo < 20 5/16/2012 Outperform 5Y $35.62 +132.87% +106.36% +26.51 0 Comment
TrackCantorFitz 41.12 4/4/2012 Outperform NS $40.00 +58.37% +11.45% +46.92 4/22/2013 @ $63.34 0 Comment
trackmizuho < 20 1/10/2012 Outperform NS $34.60 +139.77% +113.62% +26.16 0 Comment
tracksummerstree 92.88 8/17/2011 Outperform NS $28.10 +195.20% +130.91% +64.29 0 Comment
TrackZacks < 20 8/11/2011 Outperform 3M $26.83 +44.18% +17.03% +27.15 4/24/2012 @ $38.68 1 Comment
TrackJimCramer 85.70 11/12/2010 Outperform 3W $30.15 +175.12% +129.95% +45.17 0 Comment
TrackZacks < 20 10/28/2010 Outperform 3M $30.60 -7.78% +7.25% -15.02 1/10/2011 @ $28.22 1 Comment
TrackStifel 92.30 9/9/2010 Outperform NS $27.30 +203.90% +147.56% +56.34 0 Comment
TrackJimCramer 85.70 7/26/2010 Underperform 3W $27.25 +10.66% +7.74% -2.92 11/13/2010 @ $30.15 0 Comment
TrackMorganJos 81.92 7/12/2010 Outperform NS $25.84 +5.81% +20.89% -15.09 1/28/2011 @ $27.34 0 Comment
TrackJefferies 82.51 6/7/2010 Outperform NS $27.12 +205.86% +157.84% +48.03 0 Comment
TrackSoleil 96.16 12/3/2009 Outperform NS $28.75 +188.52% +147.78% +40.74 0 Comment
TrackRWBaird 87.20 9/22/2009 Outperform NS $26.77 +49.90% +37.81% +12.08 10/5/2012 @ $40.12 0 Comment
TrackCowenandCo 77.75 8/6/2009 Underperform NS $27.75 +13.08% +30.76% +17.68 6/26/2012 @ $31.38 0 Comment
trackmerriman 69.89 7/28/2009 Outperform NS $27.28 +204.07% +184.36% +19.71 0 Comment
TrackDeutscheSec 85.94 7/22/2009 Outperform NS $23.80 +248.60% +192.42% +56.19 0 Comment
TrackMorganJos 81.92 6/16/2009 Outperform NS $21.30 +30.99% +4.62% +26.37 7/24/2009 @ $27.90 0 Comment
TrackWedbush 85.65 3/20/2009 Outperform NS $22.99 +260.82% +260.22% +0.60 0 Comment
TrackOppenheimer 69.68 2/18/2009 Outperform NS $26.19 +216.72% +252.52% -35.80 0 Comment
TrackRBCCapMkts 85.24 2/4/2009 Outperform NS $26.59 -1.94% +55.42% -57.36 2/24/2011 @ $26.08 0 Comment
TrackZacks < 20 2/2/2009 Outperform 3M $26.74 -20.87% +1.24% -22.11 4/6/2009 @ $21.16 1 Comment
TrackBarclaysCap 89.18 1/7/2009 Outperform NS $25.71 +222.70% +206.66% +16.04 0 Comment
TrackRWBaird 87.20 10/13/2008 Outperform NS $28.33 -4.61% -0.79% -3.81 1/6/2009 @ $27.03 0 Comment
TrackBWS 96.71 10/10/2008 Outperform NS $26.72 +93.24% +73.44% +19.80 3/1/2013 @ $51.63 0 Comment
TrackCowenandCo 77.75 10/8/2008 Outperform NS $27.35 +1.48% +3.40% -1.92 8/6/2009 @ $27.75 0 Comment
TrackCreditSuiss 89.00 7/25/2008 Outperform NS $37.23 -43.79% -30.88% -12.91 5/1/2009 @ $20.93 0 Comment
TrackPacificGrow < 20 5/9/2008 Outperform NS $30.63 +27.83% -0.71% +28.54 4/17/2012 @ $39.16 0 Comment
TrackWellsFargo 86.59 12/4/2007 Outperform NS $30.06 +175.95% +97.45% +78.50 0 Comment
TrackBofASec 92.53 11/26/2007 Outperform NS $31.60 +162.50% +100.51% +61.99 0 Comment
TrackBMOCapital < 20 11/20/2007 Outperform NS $32.44 +155.74% +100.95% +54.79 0 Comment
TrackSwensen < 20 9/30/2007 Outperform NS $35.66 +132.65% +89.80% +42.85 1 Comment
TrackWMBlair 77.67 8/28/2007 Outperform NS $30.00 +176.50% +100.41% +76.09 0 Comment
TrackCowenandCo 77.75 8/8/2007 Outperform NS $30.92 -17.85% +1.70% -19.55 12/12/2007 @ $25.40 0 Comment
TrackJefferies 82.51 7/12/2007 Outperform NS $30.00 +3.45% -22.01% +25.46 4/9/2010 @ $31.04 0 Comment
TrackLehmanBros < 20 6/26/2007 Outperform NS $28.63 +36.76% -8.08% +44.84 4/17/2012 @ $39.16 0 Comment
TrackCreditSuiss 89.00 5/11/2007 Outperform NS $31.66 -3.68% -7.34% +3.66 5/9/2008 @ $30.50 0 Comment
TrackPiperJaff 85.65 4/5/2007 Outperform NS $28.04 +39.20% +0.18% +39.02 10/11/2012 @ $39.03 0 Comment
TrackBernstein 88.27 3/13/2007 Outperform NS $25.69 +222.95% +108.72% +114.23 0 Comment
TrackUBS 90.82 2/21/2007 Outperform NS $26.85 +36.79% -1.21% +37.99 9/10/2012 @ $36.73 0 Comment
TrackRodmanRen < 20 12/18/2006 Outperform NS $29.38 +182.38% +105.81% +76.57 0 Comment
TrackFBRCapitalM 85.82 12/11/2006 Outperform NS $28.35 +12.67% -9.70% +22.37 6/30/2008 @ $31.94 0 Comment
TrackLazardCapit 79.53 11/20/2006 Outperform NS $28.10 +195.20% +109.45% +85.75 0 Comment
TrackJMP 83.33 10/30/2006 Outperform NS $24.30 +241.43% +113.20% +128.23 0 Comment
TrackJimCramer 85.70 2/27/2006 Outperform 3W $19.23 +41.72% -14.10% +55.82 7/26/2010 @ $27.25 0 Comment

Advertisement